Mustang Bio, Inc. (MBIO)
0.37
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
Mustang Bio Enterprise Value : -12.35M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -12.35M |
| October 22, 2026 | -12.35M |
| October 21, 2026 | -12.25M |
| October 20, 2026 | -12.27M |
| October 19, 2026 | -12.32M |
| October 16, 2026 | -12.30M |
| October 15, 2026 | -12.22M |
| October 14, 2026 | -12.35M |
| October 13, 2026 | -12.29M |
| October 12, 2026 | -12.02M |
| October 09, 2026 | -12.12M |
| October 08, 2026 | -11.99M |
| October 07, 2026 | -11.74M |
| October 06, 2026 | -11.66M |
| October 05, 2026 | -11.66M |
| October 02, 2026 | -11.58M |
| October 01, 2026 | -11.61M |
| September 30, 2026 | -11.64M |
| September 29, 2026 | -11.52M |
| September 28, 2026 | -11.31M |
| September 25, 2026 | -11.21M |
| September 24, 2026 | -11.16M |
| September 23, 2026 | -11.27M |
| September 22, 2026 | -11.13M |
| September 21, 2026 | -10.98M |
| Date | Value |
|---|---|
| September 18, 2026 | -11.06M |
| September 17, 2026 | -11.44M |
| September 16, 2026 | -11.36M |
| September 15, 2026 | -11.33M |
| September 14, 2026 | -11.28M |
| September 11, 2026 | -11.31M |
| September 10, 2026 | -11.21M |
| September 09, 2026 | -11.15M |
| September 08, 2026 | -11.05M |
| September 04, 2026 | -11.04M |
| September 03, 2026 | -10.91M |
| September 02, 2026 | -11.04M |
| September 01, 2026 | -11.00M |
| August 31, 2026 | -11.08M |
| August 28, 2026 | -11.08M |
| August 27, 2026 | -10.98M |
| August 26, 2026 | -10.91M |
| August 25, 2026 | -10.97M |
| August 24, 2026 | -10.97M |
| August 21, 2026 | -10.76M |
| August 20, 2026 | -10.81M |
| August 19, 2026 | -10.80M |
| August 18, 2026 | -10.83M |
| August 17, 2026 | -10.65M |
| August 14, 2026 | -10.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.072M |
| Total Expenses (Quarterly) | 1.072M |
| EPS Diluted (Quarterly) | -0.1592 |
| Earnings Yield | -121.6% |
| Normalized Earnings Yield | -121.57 |